ClinicalTrials.gg
WithdrawnNCT02969265Updated Jun 9, 2017

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

A Phase 3 interventional study of Amlodipine and TCV-116CCB in Hypertension, sponsored by Takeda. Withdrawn at 25 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-06-09.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Business reasons unrelated to product safety

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
179th of 186
0 · median 180
Started
2017
with 8 others
Phase 3
69 of 187
2 open now
Registered
144th of 187
by date

Among the 187 studies testing amlodipine in Hypertension, this one is the 179th largest by enrollment of the 186 interventional ones that give a count, is one of 9 that started in 2017, is one of 69 in phase 3, and was the 144th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination) in Chinese participants with mild to moderate hypertension who do not reach target blood pressure following 4 weeks of treatment with amlodipine monotherapy.

Read the detailed description

The drug being tested in this study is called TCV-116CCB (candesartan cilexetil and amlodipine besylate fixed-dose combination). This study will look at blood pressure in Chinese participants with grade 1 or 2 essential hypertension.

The study will enroll approximately 370 patients. Prior to the start of study treatment, participants will undergo run-in period of 2 weeks followed by single-blind treatment period of 4 weeks. Upon completion of single-blind treatment period, participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Amlodipine 5 mg
  • TCV-116CCB (Candesartan 8 mg Plus Amlodipine 5 mg)

All participants will be asked to take one tablet/capsule at the same time each day throughout the study up to 8 weeks.

This multicenter trial will be conducted China. The overall time to participate in this study is 19 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone plus a final visit 14 days after receiving their last dose of drug for a follow-up assessment.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has grade 1 or 2 essential hypertension which is not adequately controlled, as defined by mean, trough, sitting, clinic systolic blood pressure (SBP):

    1. ≥155 to \<180 mm Hg in participants who have not received any antihypertensive medication in the 14 days prior to Visit 1.
    2. ≥145 to ≤170 mm Hg in participants taking 1 antihypertensive medication at Visit 1.
    3. ≥140 to \<160 mm Hg in participants taking 2 antihypertensive medications at Visit 1.
  2. Is willing to discontinue current antihypertensive medications.

    Entering amlodipine 5 mg monotherapy:

  3. Must have a clinic SBP measurement of 155 to 179 mm Hg inclusive (determined by the mean of 3 sitting, trough, measurements on Day -28, using same arm throughout study) to qualify for entry in to the 4 week single-blind amlodipine 5 mg monotherapy treatment period.

    At double-blind randomization:

  4. Has not achieved target blood pressure (defined as clinic SBP ≥140 mm Hg as determined by the mean of 3 sitting, trough, measurements) following 4 weeks single-blind treatment with amlodipine 5 mg monotherapy at Day 1 prior to randomization to double-blind treatment.

Exclusion criteria

Exclusion Criteria:

  1. Has clinic SBP ≥180 mm Hg or DBP ≥110 mm Hg.
  2. The participant's 3 SBP measurements differ by more than 15 mm Hg (confirmed by a second set of three measurements).
  3. Has been randomized/enrolled in an amlodipine or candesartan or candesartan/amlodipine Fixed dose combination study.
  4. Has secondary hypertension of any etiology (e.g., renovascular disease documented as the cause of hypertension, pheochromocytoma, Cushing's syndrome).
  5. Has any history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, persistent or permanent atrial fibrillation or .
  6. Has cardiac conduction defects (e.g., third-degree atrioventricular block, sick sinus syndrome).
  7. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease or hypertrophic cardiomyopathy.
  8. Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of single-blind amlodipine monotherapy study drug. (This criterion does not apply to those participants with basal cell or Stage 1 squamous cell carcinoma of the skin).
  9. Has poorly-controlled type 1 or 2 diabetes mellitus ( [HbA1c] >8.0%) at Screening.
  10. Has severe renal dysfunction or disease (based on estimated [GFR] \<30 mL/min/1.73m\^2) at Screening.
  11. Has hypokalemia or hyperkalemia (defined as serum potassium outside of the normal reference range) at Screening.
  12. Has an or aspartate aminotransferase level >2.5 times the , active liver disease, or jaundice at Screening.
  13. Works a night (third) shift (defined as 10 PM [2200] to 6 AM [0600]) (Only for participants with ambulatory blood pressure monitoring [ABPM]).
  14. Has an upper arm circumference \<24 cm or >42 cm (Only for participants with ABPM).

    Entering amlodipine 5 mg monotherapy period:

  15. Has a clinic SBP ≥180 mm Hg or DBP ≥110 mm Hg.
  16. Is non-compliant (\<80% or >120%) with study medication during the placebo run-in period.

    Post-single-blind amlodipine 5 mg treatment period:

  17. Achieves target blood pressure (defined as clinic SBP\<140 mm Hg as determined by the mean of 3 sitting, trough measurements) following 4 weeks single-blind treatment with amlodipine 5 mg monotherapy at Day 1, prior to randomization to double-blind treatment.
  18. Has a clinic SBP ≥180 mm Hg or/and DBP ≥110 mm Hg.
  19. Is non-compliant (\<80% or >120%) with study medication during the amlodipine 5 mg single-blind treatment period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TCV-116CCB (Candesartan 8 mg Plus Amlodipine 5 mg)

    Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks. Single-blind monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks. Double-blind treatment period: TCV-116CCB 8/5 mg tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 8 weeks.

    Drug: Amlodipine · Drug: TCV-116CCB · Drug: Amlodipine Placebo · Drug: TCV-116CCB Placebo

  • Experimental
    Amlodipine 5 mg

    Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks. Monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks. Double-blind treatment period: Amlodipine 5 mg capsules, orally, once daily along with TCV-116CCB placebo-matching tablets, orally, once daily up to 8 weeks.

    Drug: Amlodipine · Drug: Amlodipine Placebo · Drug: TCV-116CCB Placebo

Interventions

  • Amlodipine Capsules

  • DrugTCV-116CCB

    TCV-116CCB Tablets

  • DrugAmlodipine Placebo

    Amlodipine placebo-matching capsules

  • DrugTCV-116CCB Placebo

    TCV-116CCB 8/5 mg placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure (SBP) at Week 8

    The change between trough SBP measured at Week 8 relative to baseline. It is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure (DBP) at Week 8

    The change between trough DBP measured at Week 8 relative to baseline. It is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 8

  2. Percentage of Participants who Achieved Target Blood Pressure at Week 8

    Target blood pressure is defined as trough, sitting clinic SBP \<140 mm Hg, trough, sitting, clinic DBP \<90 mm Hg or achieving both trough, sitting clinic SBP (\<140 mm Hg) and DBP targets (\<90 mm Hg).

    Time frame: Week 8

07

Study locations

25 sites
  • Fuwai Hospital
    Beijing, Beijing 100037, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • The Second Hospital of Lanzhou University
    Lanzhou, Gansu 730030, China
  • The Second Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou 550004, China
  • Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050011, China
  • Daqing first hospital
    Daqing, Heilongjiang 163001, China
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • People's Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • The Xiangya Hospitalof Central South University
    Changsha, Hunan 410008, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Jilin Siping Central Hospital
    Siping, Jilin, China
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116027, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • People's Hospital of Liaoning Province
    Shenyang, Liaoning 110016, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200025, China
  • the Central Hospital of Xuhui District, Shanghai
    Shanghai, Shanghai 200031, China
  • Shanghai Putuo Center Hospital
    Shanghai, Shanghai 200062, China
  • First Affiliated Hospital of Xian Jiaotong University
    Xi'an, Shanxi 710061, China
  • West China Hospital, Sichuan Univeisity
    Chengdu, Sichuan 610041, China
  • Sir Run Run Hospital of Zhejiang University
    Hangzhou, Zhejiang 310016, China
  • Taizhou Hospital of Zhejiang Province
    Linhai, Zhejiang 317000, China
  • Lishui Hospital of Zhejiang Province
    Lishui, Zhejiang 323000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2017; primary completion for Jul 2018, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2016
First posted
Nov 21, 2016
StartEst.
May 9, 2017
Primary completionEst.
Jul 12, 2018
CompletionEst.
Jul 26, 2018
Last update
Jun 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02969265
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 21, 2016
Start date
May 9, 2017 (estimated)
Primary completion
Jul 12, 2018 (estimated)
Completion
Jul 26, 2018 (estimated)
Last update
Jun 9, 2017

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion